EE466 Implementing the Generalized Risk-Adjusted Cost-Effectiveness (GRACE) Model for Sickle-Cell Disease: A Case Study
| Autor: | Kleintjens, J, Mulligan, K, Hassan, T, Land, N, May, SG, Graf, M |
|---|---|
| Zdroj: | In Value in Health June 2024 27(6) Supplement:S142-S142 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect